A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2212925
下载链接
链接失效反馈官方服务：
资源简介：
The main purpose of this study is to evaluate the progression-free survival (PFS) in patients receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control arm) as first-line treatment for unresectable metastatic colorectal cancer in patients non-eligible for intensive therapy.
创建时间：
2016-04-15
